Lys-γ3-MSH(human)
Lys-γ3-MSH(human) is a melanocortin peptide derived from the C-terminal of the fragment of pro-opiomelanocortin (POMC). Lys-γ3-MSH(human) potentiates the steroidogenic response of the rat adrenal to adrenocorticotrophin (ACTH). Lys-γ3-MSH(human) is a potent stimulator of lipolysis with an apparent EC50 of 3.56 nM. Lys-γ3-MSH(human) can activate hormone sensitive lipase (HSL) and Perilipin A resulting in lipolysis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 156159-18-1
- Formule: C128H193N45O39S
- Masse moléculaire:3018.25
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-N2466
Melanotan IMelanocortin Receptor Activator -
HY-P1211
Adrenocorticotropic Hormone (ACTH) (1-39), humanMelanocortin Receptor Agonist -
HY-P0227
SHU 9119MC3/4R Antagonist -
![[D-Trp8]-γ-MSH](https://file.medchemexpress.com/product_pic/hy-p1217.gif)
HY-P1217
[D-Trp8]-γ-MSHMC3 Agonist -
HY-P1531
γ-1-Melanocyte Stimulating Hormone (MSH), amideMelanocortin Receptor Agonist -
HY-P1214
γ1-MSHMC3 Receptor Agonist -
HY-P0252
α-MSHMC4R Agonist -
HY-P1213
JKC363MC4 Receptor Antagonist -
HY-P0267
Melanotan (MT)-IIMelanotropin Receptor Agonist -
HY-P1208
PG-931Melanocortin 4 Receptor Agonist -
HY-10624
THIQMC4R Agonist -
HY-107627
MCL0020MC4 Receptor Antagonist
Activité biologique
Description
Chemical Information
-
CAS No. 156159-18-1
-
Masse moléculaire 3018.25
-
Formule C128H193N45O39S
-
Sequence
Lys-Tyr-Val-Met-Gly-His-Phe-Arg-Trp-Asp-Arg-Phe-Gly-Arg-Arg-Asn-Ser-Ser-Ser-Ser-Gly-Ser-Ser-Gly-Ala-Gly-Gln
-
Sequence Shortening
KYVMGHFRWDRFGRRNSSSSGSSGAGQ
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
Pureté et documentation
Références
[1]. Harmer SC, Pepper DJ, Cooke K, Bennett HP, Bicknell AB. Evidence of a possible role for Lys-gamma3-MSH in the regulation of adipocyte function. J Endocrinol. 2008;196(1):149-158. [Content Brief]
[2]. Bicknell KA, et al. Lys-gamma3-MSH: a global regulator of hormone sensitive lipase activity? Mol Cell Endocrinol. 2009;300(1-2):71-76. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Lys-γ3-MSH(human) Related Classifications
HY-P1210 Related Classifications
Powered by Bioz